Hoffmann-La Roche Inc.
www.rocheusa.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Hoffmann-La Roche Inc.
Formycon’s Lucentis Biosimilar Enters Swiss and Canada Markets
Switzerland and Canada mark the first market entries for Formycon’s ranibizumab biosimilar this year, with several anticipated launches in the Middle East later in 2024.
Japan Zolbetuximab Filing Heats Up CLDN18.2 Competition
Astellas says its first approval filing globally for zolbetuximab - in Japan for gastric cancer - came faster than expected, as Scrip takes a look at the latest status of other CLDN18.2-targeting candidates in late clinical trials.
Rejuveron CEO Confident About Longevity Biotech Prospects In Troubled Economy
Swiss-based Rejuveron’s diversified platform of longevity biotechs addresses key hallmarks of aging, with the goal of helping people to age better and live longer with reduced burden of age-related diseases. CEO Matthias Steger discusses the firm’s vision and the road ahead.
‘A Lot To Consider’ For Sponsors Planning Decentralized Trials
A senior MHRA official tells sponsors not to get "put off" by the many factors they need to examine when deciding on the suitability of decentralized trials, and instead seek early advice from regulators.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice